ProteKt Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

ProteKt Therapeutics General Information

Description

Operator of a drug development company intended to develop inhibitors to treat neurodegenerative and neuroinflammatory diseases in patients. The company developed a series of novel and selective molecules by applying unique computational methods and validating the inhibitors in clinically relevant assays, enabling patients to improve memory consolidation impairment and enhance long-term memory.

Contact Information

Website
www.protektx.com
Formerly Known As
MemoFit
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • At: Eli, Nadler and Company Law Firm
  • Noa House, 16 Bar-Kochva Street 4th Floor
  • Beni-Brak 5126107
  • Israel
+972
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Bukwang Pharmaceutical
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • At: Eli, Nadler and Company Law Firm
  • Noa House, 16 Bar-Kochva Street 4th Floor
  • Beni-Brak 5126107
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProteKt Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 26-Jan-2023 Completed Pre-Clinical Trials
3. Seed Round 12-Nov-2019 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Dec-2015 $2.25M $2.25M Completed Pre-Clinical Trials
1. Spin-Off 01-Dec-2014 Completed Startup
To view ProteKt Therapeutics’s complete valuation and funding history, request access »

ProteKt Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Preferred A
To view ProteKt Therapeutics’s complete cap table history, request access »

ProteKt Therapeutics Patents

  • 4

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

ProteKt Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023410062-A1 Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors Pending 22-Dec-2022
EP-4638450-A1 Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors Pending 22-Dec-2022
US-20260209225-A1 Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors Pending 22-Dec-2022
WO-2024134657-A1 Pyrrolopyridine and pyrrolopyridazine based compounds and use thereof as pkr inhibitors Inactive 22-Dec-2022 C07D471/04

ProteKt Therapeutics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Carmel-Haifa University Economic Corporation Venture Capital Minority
Fonds de solidarite FTQ PE/Buyout Minority
FutuRx Accelerator/Incubator Minority
Johnson & Johnson JJDC Corporate Venture Capital Minority
OrbiMed Growth/Expansion Minority
You’re viewing 5 of 7 investors. Get the full list »

Ready to get started?

Request a free trial

ProteKt Therapeutics FAQs

  • When was ProteKt Therapeutics founded?

    ProteKt Therapeutics was founded in 2014.

  • Where is ProteKt Therapeutics headquartered?

    ProteKt Therapeutics is headquartered in Beni-Brak, Israel.

  • What industry is ProteKt Therapeutics in?

    ProteKt Therapeutics’s primary industry is Drug Discovery.

  • Is ProteKt Therapeutics a private or public company?

    ProteKt Therapeutics is a Private company.

  • What is ProteKt Therapeutics’s current revenue?

    The current revenue for ProteKt Therapeutics is .

  • How much funding has ProteKt Therapeutics raised over time?

    ProteKt Therapeutics has raised $6.35M.

  • Who are ProteKt Therapeutics’s investors?

    Carmel-Haifa University Economic Corporation, Fonds de solidarite FTQ, FutuRx, Johnson & Johnson JJDC, and OrbiMed are 5 of 7 investors who have invested in ProteKt Therapeutics.

  • When was ProteKt Therapeutics acquired?

    ProteKt Therapeutics was acquired on 26-Jan-2023.

  • Who acquired ProteKt Therapeutics?

    ProteKt Therapeutics was acquired by Bukwang Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process